Hudson Frederick M. 4

What Happened Hudson Frederick M., a director of Supernus Pharmaceuticals, received two awards of restricted stock units (RSUs) on Feb 18, 2026 totaling 7,966 RSUs (2,989 and 4,977). Each RSU was recorded at $0.00 (no cash paid); the awards are derivative grants that will convert into common stock upon vesting. This is an award/grant (code A) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Form filed: 2026-02-20 (filed two days after the grant).
• Awards: 2,989 RSUs and 4,977 RSUs, total 7,966 RSUs; price recorded $0.00 (no purchase price).
• Vesting/settlement: RSUs will be settled in common stock upon vesting on February 18, 2027 (footnotes F1, F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Other footnote: F3 notes "Each option vests on February 18, 2027" though no options were reported in this filing.
• Filing timeliness: appears timely (filed within two calendar days of the transaction).

Context RSU grants are compensation awards and do not necessarily signal immediate buying or selling intent; they become actual shares only if and when they vest and are settled. Because no cash was paid and the units vest one year later, there was no immediate change in Hudson’s tradable share count at the time of the filing.